Episurf Medical: Expansion of the European sales organization
Episurf Medical (NASDAQ: EPIS B) today announces two additions to the European sales organization.
JAMO Orthopaedics has been appointed agent for the Episealer® Knee and Episealer® Talus in certain areas in the UK. JAMO Orthopaedics is an orthopaedic distributor focusing on the Midlands, and acts as a distributor or agent for several global orthopaedic companies. JAMO Orthopaedic will work alongside Episurf Medicals existing sales force in the UK.
“JAMO Orthopaedics are excited and proud to be working alongside Episurf in the UK. With an evermore need for patient specific implants to treat complex conditions, the Episurf range of products will further allow JAMO to offer individualized solutions to our surgeons and their patients”, says James Nuttall and Amo Bassi, founders, JAMO Orthopaedics.
“In the coming years, the UK market will be a key market for Episurf Medical, representing a significant commercial opportunity. We are in the early stages of launching in the UK, focusing on regulatory, re-imbursement and clinical education. However, we aim at initiating a broader commercialization in the UK shortly, and JAMO Orthopaedics will play an important role in these efforts”, says Pål Ryfors, CEO Episurf Medical.
Further, Episurf Medical today also announces the hiring of a senior sales rep in the Benelux region. Episurf Medical had representation in the region up to and including 2019, but later the region was de-prioritized awaiting the clinical data supporting a broader product launch. Now, Episurf Medical has hired an experienced sales rep and look forward to expanding further in the region.
“Adding senior sales executives with market leading networks is key for any orthopaedic company, and I am very pleased to take this step in Benelux, as the region is important in our long-term planning” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.